CA2743459A1 - Isolated renal cells and uses thereof - Google Patents

Isolated renal cells and uses thereof Download PDF

Info

Publication number
CA2743459A1
CA2743459A1 CA2743459A CA2743459A CA2743459A1 CA 2743459 A1 CA2743459 A1 CA 2743459A1 CA 2743459 A CA2743459 A CA 2743459A CA 2743459 A CA2743459 A CA 2743459A CA 2743459 A1 CA2743459 A1 CA 2743459A1
Authority
CA
Canada
Prior art keywords
cells
cell
cell population
kidney
epo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2743459A
Other languages
English (en)
French (fr)
Inventor
Sharon Presnell
Andrew Bruce
Shay M. Wallace
Sumana Choudhury
Russell W. Kelley
Manuel J. Jayo
Eric S. Werdin
Patricia D. Tatsumi
Jessica J. Reinsch
Timothy A. Bertram
Oluwatoyin A. Knight
Roger.M. Ilagan
H. Scott Rapoport
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prokidney Corp
Original Assignee
Tengion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tengion Inc filed Critical Tengion Inc
Publication of CA2743459A1 publication Critical patent/CA2743459A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2743459A 2008-11-12 2009-11-12 Isolated renal cells and uses thereof Pending CA2743459A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US11403008P 2008-11-12 2008-11-12
US11402508P 2008-11-12 2008-11-12
US61/114,030 2008-11-12
US61/114,025 2008-11-12
US20105608P 2008-12-05 2008-12-05
US61/201,056 2008-12-05
US20130508P 2008-12-08 2008-12-08
US61/201,305 2008-12-08
US12131108P 2008-12-10 2008-12-10
US61/121,311 2008-12-10
PCT/US2009/006085 WO2010056328A1 (en) 2008-11-12 2009-11-12 Isolated renal cells and uses thereof

Publications (1)

Publication Number Publication Date
CA2743459A1 true CA2743459A1 (en) 2010-05-20

Family

ID=41625133

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2743459A Pending CA2743459A1 (en) 2008-11-12 2009-11-12 Isolated renal cells and uses thereof

Country Status (9)

Country Link
US (5) US8318484B2 (https=)
EP (3) EP2662440B1 (https=)
JP (5) JP5974233B2 (https=)
KR (6) KR102428795B1 (https=)
CN (2) CN103937737B (https=)
AU (5) AU2009314552B2 (https=)
CA (1) CA2743459A1 (https=)
NZ (2) NZ593207A (https=)
WO (1) WO2010056328A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101827933B (zh) 2007-06-08 2014-01-29 韦克福里斯特大学健康科学院 治疗肾功能衰竭的选择性细胞疗法
US10590391B2 (en) 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
KR102428795B1 (ko) * 2008-11-12 2022-08-04 인리젠 분리된 신장 세포 및 이의 용도
CA2780320A1 (en) 2009-11-12 2011-05-19 Tengion, Inc. Rational design of regenerative medicine products
TWI762890B (zh) 2010-05-12 2022-05-01 開曼群島商英瑞金公司 生物活性腎細胞
CA3065694A1 (en) * 2010-11-10 2012-05-18 Inregen Methods of forming injectable formulations for providing regenerative effects to an organ such as a kidney
ES2689265T3 (es) * 2011-11-04 2018-11-12 Inregen Cribado de fármacos y ensayos de potencia
RU2702721C2 (ru) * 2012-10-24 2019-10-09 инРиджен Популяции клеток почек и их применение
GB2516196B (en) * 2013-01-25 2015-09-09 Xcell Biosciences Inc Methods, compositions, kits, and systems for selective enrichment of target cells
EP4299721A3 (en) * 2013-05-08 2024-04-24 ProKidney Organoids comprising isolated renal cells and uses thereof
KR102771841B1 (ko) * 2015-11-06 2025-02-24 벤타나 메디컬 시스템즈, 인코포레이티드 대표 진단법
WO2018022108A1 (en) * 2016-07-29 2018-02-01 Deepak Jain Bioactive renal cells for the treatment of chronic kidney disease
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
BR112019027086A2 (pt) 2017-06-21 2020-07-07 Timothy A. Bertram células renais bioativas imunoprivilegiadas para o tratamento de doença renal
CN108251352B (zh) * 2018-02-01 2021-07-06 伯仕利生物科技发展（盐城）有限公司 一种血管内皮干细胞的培养方法
EP3843760A4 (en) 2018-08-31 2022-11-09 Timothy Bertram COMPOSITIONS WITH CELL-DERIVED VESICLES AND THEIR USES
WO2021177387A1 (ja) * 2020-03-04 2021-09-10 株式会社メトセラ エリスロポエチン産生能が亢進された線維芽細胞
WO2021176420A1 (en) 2020-03-06 2021-09-10 ReGenesys BVBA Biocompatible scaffolds for culturing post natal progenitor cells
CN112107600B (zh) * 2020-10-26 2024-04-05 张哲� 一种治疗色素沉着性疾病的纳米制剂及其制备方法
EP4243837A4 (en) * 2020-11-13 2025-01-15 Timothy A. Bertram ENRICHED BIOACTIVE KIDNEY CELL POPULATIONS, PROPERTIES AND USES THEREOF
CN114703120B (zh) * 2022-03-17 2024-02-02 上海纽仁生物医药科技有限公司 一种动物神经系统血管平滑肌细胞单细胞的分离方法
CN114507642B (zh) * 2022-03-17 2024-02-02 上海纽仁生物医药科技有限公司 一种动物神经系统周细胞单细胞的分离方法
US20250367238A1 (en) * 2022-06-29 2025-12-04 Pro Kidney Selected renal cell populations, characteristics and uses thereof
CN120869743B (zh) * 2025-09-29 2025-12-05 北京泛生子基因科技有限公司 一种用细胞系制备ffpe质控品的方法，参考品以及试剂盒

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US5266480A (en) * 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5863531A (en) 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4769037A (en) * 1986-10-28 1988-09-06 Midcalf Robert J Artificial replacement kidney implant and method of dialyzing blood
GB8722854D0 (en) * 1987-09-29 1987-11-04 Hardy S M Implantable artificial kidney
US5085629A (en) * 1988-10-06 1992-02-04 Medical Engineering Corporation Biodegradable stent
CN1053698C (zh) 1989-01-19 2000-06-21 南京大学 细胞培养生产促红细胞生成素的方法
DE69017820T2 (de) 1989-04-25 1995-10-05 Children's Medical Center Corp., Boston, Mass. Implantaten für grosse mengen von zellen auf polymerische matrizen.
US4996154A (en) * 1989-05-04 1991-02-26 Millipore Corporation Method for growing cellular tissue
AU2900792A (en) 1991-10-24 1993-05-21 Children's Medical Center Corporation Neomorphogenesis of urological structures in vivo from cell culture
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5549674A (en) * 1992-03-02 1996-08-27 The Regents Of The University Of Michigan Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
US6060270A (en) * 1992-03-02 2000-05-09 The University Of Michigan Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
US6410320B1 (en) * 1992-03-02 2002-06-25 The University Of Michigan Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
US5429938A (en) * 1992-03-02 1995-07-04 University Of Michigan Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
US5545131A (en) * 1994-04-28 1996-08-13 White Eagle International Technologies, Lp Artificial kidney
US6673339B1 (en) * 1996-09-05 2004-01-06 Children's Medical Center Corporation Prosthetic kidney and its use for treating kidney disease
WO1998009582A1 (en) * 1996-09-05 1998-03-12 Children's Medical Center Corporation Prosthetic kidney and its use for treating kidney disease
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
JP4235987B2 (ja) * 1996-12-19 2009-03-11 マグナチップセミコンダクター有限会社 ビデオフレームレンダリングエンジン
US5854006A (en) * 1997-03-28 1998-12-29 The University Of Virginia Gamma-glutamyl transpeptidase-specific antibody, prodrugs for the treatment of gamma-glutamyl transpeptidase-expressing tumors, and methods of administration thereof
US6946246B1 (en) * 1997-04-08 2005-09-20 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Production of functional proteins: balance of shear stress and gravity
US6224893B1 (en) 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
JP2004155788A (ja) * 1998-09-24 2004-06-03 Tanabe Seiyaku Co Ltd 腎疾患治療薬およびそのスクリーニング方法
US6777205B1 (en) * 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US6747002B2 (en) * 1999-05-11 2004-06-08 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US20040167634A1 (en) * 1999-05-26 2004-08-26 Anthony Atala Prosthetic kidney and its use for treating kidney disease
WO2000073791A1 (fr) 1999-05-27 2000-12-07 Tanabe Seiyaku Co., Ltd. Remedes pour affections renales et procede de criblage de tels medicaments
KR100369788B1 (ko) 1999-09-03 2003-01-29 동아제약 주식회사 재조합 인간 에리트로포이에틴의 제조방법
US6376244B1 (en) * 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US7326570B2 (en) * 2000-06-16 2008-02-05 The Regents Of The University Of California Induction of tubular morphogenesis using pleiotrophin
ATE392907T1 (de) * 2000-07-28 2008-05-15 Anika Therapeutics Inc Bioabsorbierbare kompositmaterialien aus derivatisierter hyaluronsäure
AU2002248237A1 (en) * 2000-10-30 2002-08-12 Zymogenetics, Inc. Compositions and methods for improving kidney function
WO2002061053A1 (en) 2001-01-31 2002-08-08 The General Hospital Corporation Renal stem cells and uses thereof
US20040152190A1 (en) * 2001-05-31 2004-08-05 Masaya Sumita Method of separating and concentrating cells for kidney regfneration
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
BR0214217A (pt) * 2001-11-16 2004-09-21 Childrens Medical Center Aumento de função de órgão
US20030180268A1 (en) * 2002-02-05 2003-09-25 Anthony Atala Tissue engineered construct for supplementing or replacing a damaged organ
WO2003080038A1 (en) 2002-03-22 2003-10-02 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for kidney disease
US8084424B2 (en) * 2003-04-09 2011-12-27 University Of Utah Research Foundation Compositions and methods related to erythropoietin
US20060153894A1 (en) * 2004-06-30 2006-07-13 Ragae Ghabrial Multi-compartment delivery system
WO2006055412A1 (en) * 2004-11-19 2006-05-26 Shiva Biomedical, Llc Methods of treating erythropoietin-resistance
WO2007035843A2 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US7850983B2 (en) * 2006-02-07 2010-12-14 Spinalcyte, Llc Methods and compositions for repair of cartilage using an in vivo bioreactor
CA2871840A1 (en) 2006-02-10 2007-08-23 Tengion, Inc. Scaffolds for organ reconstruction and augmentation
WO2007125916A1 (ja) * 2006-04-24 2007-11-08 Stemcell Institute Inc. 移植用臓器の調製方法
CN101595212B (zh) * 2006-10-12 2014-04-30 伊西康公司 肾源细胞及在组织修复和再生中的使用方法
AU2007319214B2 (en) 2006-11-16 2014-04-17 Genentech, Inc. Genetic variations associated with tumors
US20110008347A1 (en) 2006-12-01 2011-01-13 Agency For Science ,Technology And Research Cancer-related protein kinases
US9580688B2 (en) * 2007-06-08 2017-02-28 Wake Forest University Health Sciences Kidney structures and methods of forming the same
CN101827933B (zh) * 2007-06-08 2014-01-29 韦克福里斯特大学健康科学院 治疗肾功能衰竭的选择性细胞疗法
US10590391B2 (en) * 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
KR102428795B1 (ko) * 2008-11-12 2022-08-04 인리젠 분리된 신장 세포 및 이의 용도
JP5565607B2 (ja) 2009-07-15 2014-08-06 国立大学法人 東京大学 敗血症又は多臓器不全の予後診断方法及び予後診断用キット

Also Published As

Publication number Publication date
US8318484B2 (en) 2012-11-27
HK1197267A1 (en) 2015-01-09
JP2018148909A (ja) 2018-09-27
AU2020239736A1 (en) 2020-10-15
AU2019202099A1 (en) 2019-04-18
JP5974233B2 (ja) 2016-08-24
WO2010056328A9 (en) 2011-05-19
US10105392B2 (en) 2018-10-23
EP2358375A1 (en) 2011-08-24
US20110117162A1 (en) 2011-05-19
CN103937737A (zh) 2014-07-23
JP2021100428A (ja) 2021-07-08
AU2017202897A1 (en) 2017-05-25
JP2016028578A (ja) 2016-03-03
US9192629B2 (en) 2015-11-24
JP7685688B2 (ja) 2025-05-30
AU2020239736B2 (en) 2024-02-08
HK1157190A1 (en) 2012-06-29
EP2662440B1 (en) 2018-04-25
CN102271692B (zh) 2014-05-21
AU2009314552A1 (en) 2011-06-30
US20240108657A1 (en) 2024-04-04
US20160206659A1 (en) 2016-07-21
AU2019202099B2 (en) 2020-10-08
EP2358375B1 (en) 2013-07-24
EP3388509A1 (en) 2018-10-17
WO2010056328A1 (en) 2010-05-20
JP2023100876A (ja) 2023-07-19
KR20240091315A (ko) 2024-06-21
US20130149347A1 (en) 2013-06-13
JP2012508691A (ja) 2012-04-12
KR101893717B1 (ko) 2018-08-30
KR101735125B1 (ko) 2017-05-15
JP7625287B2 (ja) 2025-02-03
KR102428795B1 (ko) 2022-08-04
KR20170045385A (ko) 2017-04-26
AU2024203036A1 (en) 2024-05-30
KR20180097788A (ko) 2018-08-31
CN103937737B (zh) 2023-05-23
EP2662440A1 (en) 2013-11-13
NZ593207A (en) 2012-10-26
CN102271692A (zh) 2011-12-07
KR20220112862A (ko) 2022-08-11
KR102357077B1 (ko) 2022-01-27
AU2009314552B2 (en) 2017-02-02
KR20200138830A (ko) 2020-12-10
US20190117695A1 (en) 2019-04-25
AU2017202897B2 (en) 2019-04-18
KR20110100213A (ko) 2011-09-09
NZ601862A (en) 2014-07-25
KR102672712B1 (ko) 2024-06-07

Similar Documents

Publication Publication Date Title
AU2020239736B2 (en) Isolated renal cells and uses thereof
HK1262284A1 (en) Isolated renal cells and uses thereof
HK1189630B (en) Isolated renal cells and uses thereof
HK1189630A (en) Isolated renal cells and uses thereof
HK1157190B (en) Isolated renal cells and uses thereof
HK1197267B (en) Isolated renal cells and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141016

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241108

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241108

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250617

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250617

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20251010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251010

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260126

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260225